Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CureVac (DE:5CV)
XETRA:5CV
Holding DE:5CV?
Track your performance easily
5CV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.11 - €5.71
Previous Close€2.62
Volume161.85K
Average Volume (3M)81.85K
Market Cap
€594.41M
Enterprise Value€233.78M
Total Cash (Recent Filing)€402.45M
Total Debt (Recent Filing)€41.82M
Price to Earnings (P/E)5.4
Beta1.11
Next Earnings
Apr 23, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding223,988,675
10 Day Avg. Volume94,808
30 Day Avg. Volume81,849
Standard Deviation0.25
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.00
Price to Sales (P/S)22.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.52Price Target Upside263.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
CureVac News
PremiumCompany Announcements
CureVac Reports Significant Revenue Growth Amid Strategic Restructuring
PremiumCompany Announcements
CureVac Reports Surging Revenues and Profit Growth
PremiumCompany Announcements
CureVac’s Financial Upsurge and Strategic RestructuringBulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue significantly surpassed expectations, driven by a new GSK license agreement and contributions from other collaborations.
Immunogenicity ResultsCell-mediated immunogenicity particularly encouraging, with the majority having evidence of antigen-specific CD8 and/or CD4 T-cell responses.
Partnership MilestoneCureVac's partner GSK expects to advance to Phase 3 with a seasonal flu mRNA vaccine, which earns CureVac a significant milestone.
Bears Say
Financial ImpactCash was impacted by over €80 million due to continued resolution of obligations from the first-gen COVID-19 vaccine.
Legal ChallengesIP litigation directed at the COVID-19 vaccines is ongoing in the U.S. and Europe/UK.
Workforce ReductionA 30% workforce reduction is expected to complete by the end of the year as part of the company's restructuring efforts.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
0.08% Mutual Funds
1.03% Other Institutional Investors
97.69% Public Companies and
Individual Investors
5CV FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was €2.11 and its highest was €5.71 in the past 12 months.
What is CureVac’s market cap?
Currently, no data Available
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Apr 23, 2025 which is in 147 days.
How were CureVac’s earnings last quarter?
CureVac released its earnings results on Nov 12, 2024. The company reported €1.51 earnings per share for the quarter, beating the consensus estimate of €1.41 by €0.1.
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CureVac have?
CureVac has 224,305,680 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
CureVac reported an EPS of €1.51 in its last earnings report, beating expectations of €1.41. Following the earnings report the stock price went down -0.685%.
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is Platinum Investment Management. It holds CureVac’s shares valued at N/A.
---
CureVac Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.52 (263.32% Upside)
€9.52 (263.32% Upside)
Blogger Sentiment
Bearish
DE:5CV Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.72%
12-Months-Change
Fundamentals
Return on Equity
17.08%
Trailing 12-Months
Asset Growth
6.87%
Trailing 12-Months
Company Description
CureVac
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
---
5CV Earnings Call
Q3 2024
0:00 / 0:00
---
5CV Stock 12 Month Forecast
Average Price Target
€9.52
▲(263.32% Upside)
Technical Analysis
Best Analysts Covering 5CV
1 Year
1 Year Success Rate
1/25 ratings generated profit
1 Year Average Return
-38.94%
reiterated a buy rating 13 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 4.00% of your transactions generating a profit, with an average return of -38.94% per trade.
---